> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Boehringer Gets Breakthrough on Pulmonary Fibrosis Drug
- URL: https://www.fdaweb.com/boehringer-gets-breakthrough-on-pulmonary-fibrosis-drug/
- Published: 2022-02-24T12:00:00.000Z
- Updated: 2026-09-14T17:34:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151235

FDA has granted Boehringer Ingelheim Pharmaceuticals a breakthrough therapy designation for its investigational therapy BI 1015550 and its use in treating idiopathic pulmonary fibrosis. The company says the oral phosphodiesterase 4B inhibitor has the potential to address both pulmonary fibrosis, which is the scarring of lung tissue, and inflammation associated with progressive fibrosing interstitial lung diseases. BI 1015550 has been studied as a monotherapy and in combination with background antifibrotic therapy to assess the effectiveness of slowing the rate of lung function decline in patients with idiopathic pulmonary fibrosis (*see clinical trial information here*: [NCT04419506](https://c212.net/c/link/?t=0&l=en&o=3453745-1&h=1951033577&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04419506%3Fterm%3DBI%2B1015550%26draw%3D2%26rank%3D3&a=%28NCT04419506%29&ref=fdaweb.com)).